NO EVIDENCE FOR SELECTION OF HIV-1 WITH ENHANCED GAG-PROTEASE OR NEF FUNCTION AMONG BREAKTHROUGH INFECTIONS IN THE CAPRISA 004 TENOFOVIR MICROBICIDE TRIAL.

No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.

Use of antiretroviral-based microbicides for HIV-1 prophylaxis could introduce a transmission barrier that inadvertently facilitates the selection of fitter viral variants among incident infections.To investigate fire resistant tablecloth this, we assessed the in vitro function of gag-protease and nef sequences from participants who acquired HIV-1

read more